Literature DB >> 16738866

Expression of P-glycoprotein in lymphocytes of children with nephrotic syndrome treated with glucocorticoids.

Anna M Wasilewska1, Walentyna M Zoch-Zwierz, Mirosława Pietruczuk.   

Abstract

INTRODUCTION: Glucocorticoids are still the mainstay of therapy for nephrotic syndrome (NS) in children. Poor response to glucocorticoids may relate, in part, to the overexpression of P-glycoprotein (P-gp). The aim of the present study was to determine the expression of P-gp in lymphocytes (CD3) in the peripheral blood of children with steroid-sensitive nephrotic syndrome in the dynamics of the disease. The study group (I) consisted of 18 children, median age 5.75 years, with steroid-sensitive nephrotic syndrome, in whom the examinations were carried out three times: (A) before treatment, during relapse; (B) after 3-4 weeks of prednisone treatment; (C) 2 months after finishing prednisone treatment. The control group (II) consisted of 18 healthy children of the same age. P-gp expression in CD3 lymphocytes of peripheral blood was measured using flow cytometry. During NS relapse and prior to glucocorticoid administration, the CD3/P-gp level was higher (median 3.20%, range 0.80-7.80%) when compared to healthy controls (1.10%, range 0.30- 2.20%) (p<0.01). During glucocorticoid treatment, CD3/P-gp increased significantly and was much higher than in the control group (p<0.01) and in the NS children before treatment (p<0.01). In remission, the P-gp expression decreased, but did not achieve the values of the controls (p<0.05). Fourteen out of eighteen (14/18) children still showed P-gp values above the cut-off level. We also found a positive correlation between the P-gp expression and total prednisone dose in the NS children in all examinations: A: (r=0.540, p<0.05); B: (r=0.630, p<0.01); C: (r=0.653, p<0.01).
CONCLUSION: In conclusion, the overexpression of P-gp in remission, after finishing glucocorticoid treatment, may indicate that P-gp plays a role in the response to corticosteroids in nephrotic children.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16738866     DOI: 10.1007/s00431-006-0177-1

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  24 in total

1.  Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE).

Authors:  R J Hogg; R J Portman; D Milliner; K V Lemley; A Eddy; J Ingelfinger
Journal:  Pediatrics       Date:  2000-06       Impact factor: 7.124

Review 2.  Glucocorticoid resistance in inflammatory bowel disease.

Authors:  R J Farrell; D Kelleher
Journal:  J Endocrinol       Date:  2003-09       Impact factor: 4.286

3.  Expression of glucocorticoid receptors in nephrotic children depending on total prednisone dose.

Authors:  Anna Wasilewska; Walentyna Zoch-Zwierz
Journal:  J Pediatr Endocrinol Metab       Date:  2005-08       Impact factor: 1.634

4.  Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: Increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control.

Authors:  A Diaz-Borjon; Y Richaud-Patin; C Alvarado de la Barrera; J Jakez-Ocampo; A Ruiz-Argüelles; L Llorente
Journal:  Joint Bone Spine       Date:  2000-01       Impact factor: 4.929

Review 5.  Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

Authors:  V J Wacher; C Y Wu; L Z Benet
Journal:  Mol Carcinog       Date:  1995-07       Impact factor: 4.784

Review 6.  Biochemistry of multidrug resistance mediated by the multidrug transporter.

Authors:  M M Gottesman; I Pastan
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

7.  Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone.

Authors:  J F Maillefert; M Maynadie; J G Tebib; S Aho; P Walker; C Chatard; V Dulieu; M Bouvier; P M Carli; C Tavernier
Journal:  Br J Rheumatol       Date:  1996-05

Review 8.  Chromatin remodeling by nuclear receptors.

Authors:  Pratibha B Hebbar; Trevor K Archer
Journal:  Chromosoma       Date:  2003-02-26       Impact factor: 4.316

9.  High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura.

Authors:  Adam S Levy; Susanna Cunningham-Rundles; BethAnne Mazza; Maciej Simm; Richard Gorlick; James Bussel
Journal:  Br J Haematol       Date:  2002-09       Impact factor: 6.998

10.  The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children.

Authors: 
Journal:  J Pediatr       Date:  1981-04       Impact factor: 4.406

View more
  8 in total

1.  Glutathione-S-transferase-P1 I105V polymorphism and response to antenatal betamethasone in the prevention of respiratory distress syndrome.

Authors:  Chiara Oretti; Sara Marino; Fabio Mosca; Maria Rosa Colnaghi; Sara De Iudicibus; Ilenia Drigo; Gabriele Stocco; Fiora Bartoli; Giuliana Decorti; Sergio Demarini
Journal:  Eur J Clin Pharmacol       Date:  2009-01-29       Impact factor: 2.953

2.  Expression of multidrug resistance P-glycoprotein on lymphocytes from nephrotic children treated with cyclosporine A and ACE-inhibitor.

Authors:  Anna Wasilewska; Walentyna Zoch-Zwierz; Mirosława Pietruczuk
Journal:  Eur J Pediatr       Date:  2006-09-22       Impact factor: 3.183

3.  Expression of P-glycoprotein in lymphocytes from children with nephrotic syndrome, depending on their steroid response.

Authors:  Anna Wasilewska; Walentyna Zoch-Zwierz; Miroslawa Pietruczuk; Grzegorz Zalewski
Journal:  Pediatr Nephrol       Date:  2006-06-08       Impact factor: 3.714

4.  Persistent expression and function of P-glycoprotein on peripheral blood lymphocytes identifies corticosteroid resistance in patients with systemic lupus erythematosus.

Authors:  Amit Kansal; Deepak Tripathi; Mohit K Rai; Vikas Agarwal
Journal:  Clin Rheumatol       Date:  2015-09-29       Impact factor: 2.980

5.  MDR1 polymorphisms and idiopathic nephrotic syndrome in Slovak children: preliminary results.

Authors:  Martina Cizmarikova; Ludmila Podracka; Lucia Klimcakova; Viera Habalova; Andrej Boor; Jan Mojzis; Ladislav Mirossay
Journal:  Med Sci Monit       Date:  2015-01-06

Review 6.  Targeting Glycoproteins as a therapeutic strategy for diabetes mellitus and its complications.

Authors:  Rozita Naseri; Seyed Jafar Navabi; Zeinab Samimi; Abhay Prakash Mishra; Manisha Nigam; Harish Chandra; Ahmed Olatunde; Habibu Tijjani; Raquel P Morais-Urano; Mohammad Hosein Farzaei
Journal:  Daru       Date:  2020-01-31       Impact factor: 3.117

Review 7.  A PRISMA-compliant meta-analysis of MDR1 polymorphisms and idiopathic nephrotic syndrome: Susceptibility and steroid responsiveness.

Authors:  Shi-Sheng Han; Yan-Qiu Xu; Yan Lu; Xiang-Chen Gu; Yi Wang
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.817

8.  Assessment of the Link of ABCB1 and NR3C1 gene polymorphisms with the prednisolone resistance in pediatric nephrotic syndrome patients of Bangladesh: A genotype and haplotype approach.

Authors:  Most Nazma Parvin; Md Abdul Aziz; Sikder Nahidul Islam Rabbi; Mir Md Abdullah Al-Mamun; Mohammed Hanif; Md Saiful Islam; Mohammad Safiqul Islam
Journal:  J Adv Res       Date:  2021-02-17       Impact factor: 10.479

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.